<DOC>
	<DOCNO>NCT01188967</DOCNO>
	<brief_summary>The purpose research study find investigational drug , GSK598809 help people recently quit smoking ; investigator want find continue take GSK598809 six week help prevent smoker relapse . To relapse mean `` fall back '' smoking quitting . The investigator also want find GSK598809 safe take without cause many side effect .</brief_summary>
	<brief_title>Effectiveness GSK598809 , Selective D3 Antagonist , Added CBT NRT Smoking Cessation Relapse Prevention</brief_title>
	<detailed_description>We propose conduct first test effect dopamine D3 receptor antagonist , GSK598809 , smoke behavior treatment start immediately follow quit date . To , propose conduct 10-week , double-blind , placebo-controlled , proof mechanism study 90 adult smoker . Participants complete baseline evaluation . They receive manualized cognitive behavioral therapy , begin prior quit date , set quit date day week 2 study visit . They give short act NRT ( gum lozenge ) use quit date . They ask arrive week 2 visit 18-24 hour abstinence expire air CO â‰¤ 10ppm . Those randomly assign receive double blind GSK598809 identical placebo six week . Participants begin double blind GSK598809 placebo , conjunction prn NRT 8 mg per day two week . Participants continue double blind GSK598809 placebo absence NRT 4 week . At end period ( week 8 study ) , participant follow 2 week discontinuation double blind treatment complete 10 week study .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Exclusion criterion : 1 . Pregnant able become pregnant willing use approve contraception . 2 . Breastfeeding plan breastfeed study lactate within month prior enrollment . 3 . Has follow medical conditions/situations : Severe unstable COPD Asthma Bundle branch block Evidence active neurological disease , include current migraine headache require chronic treatment . Clinically significant renal dysfunction eGFR &lt; 60 History tissue/organ transplant Total fasting cholesterol triglycerides great 2 time upper limit normal Previous current history cancer , include skin cancer Serum Prolactin &gt; 25 ng/mL time screen randomization Evidence chronic liver disease ALT , AST , alkaline phosphatase value &gt; 1.5 time upper limit normal , total bilirubin value &gt; upper limit normal , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) Positive screen Hepatitis B surface antigen Hepatitis C antibody , positive result within 3 month screen A positive test HIV antibody Any unstable cardiovascular pulmonary disease , medication say disease change past 3 month , medication list excluded medication list . 4 . Is unlikely cooperate unable follow procedure outline protocol 5 . Use tobaccocontaining product cigarette ( e.g. , cigar , pipe ) unwilling discontinue use quit date . 6 . Abuse dependence substance nicotine caffeine past 6 month . 7 . Diagnosis major depressive disorder past 6 month . 8 . Lifetime DSMIV diagnosis organic mental disorder , schizophrenia , schizoaffective disorder , bipolar disorder , delusional disorder psychotic disorder elsewhere classify determined SCID . 9 . History multiple adverse drug reaction . 10 . Has participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 11 . Urine positive drug abuse screen prerandomization visit . 12 . Alcohol abuse , define selfreport average weekly intake &gt; 21 standard drink average daily intake &gt; 3 standard drink ( male ) average weekly intake &gt; 14 standard drink average daily intake &gt; 2 standard drink ( female ) past 6 month . One unit equivalent halfpint ( 220mL ) beer one ( 25mL ) measure spirit one glass ( 125mL ) wine . Participants advise minimize alcohol consumption study , may potential additive effect study medication alcohol , potentially cause great sedation feel intoxication alcohol alone . 13 . Has expose four new chemical entity within 12 month prior first day doubleblind treatment phase . 14 . Has use nonprescription drug herbal medicine centrally active within 14 day prior first dose day , exception nondaily PRN use acetaminophen ibuprofen daily use vitamin . 15 . Has ever use chronic antipsychotic , antiepileptic , mood stabilize medication ; use antianxiety medication , antidepressant medication , prescription sedative hypnotic within 5 half life two week randomization , whichever great . 16 . Has history sensitivity study medication , component thereof history drug allergy , opinion investigator make participation contraindicate . 17 . Has donate blood participation study would result donation blood blood product excess 500 ml within 56day period . 18 . Has fail smoke cessation attempt use adequate smoking cessation pharmacotherapy within last month . 19 . Current Axis II DSMIV diagnosis may interfere conduct study . 20 . Personal family history long QT syndrome , personal family history unexplained syncope , family history unexplained sudden death . 21 . Currently use , use within month prior study start , drug cause prolongation QT interval . 22 . Currently use HMG CoA Reductase Inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Nicotine Dependence</keyword>
	<keyword>Therapies Relapse Nicotine</keyword>
	<keyword>Relapse Prevention</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Nicotine Cessation Therapies</keyword>
</DOC>